Formulation Laboratory, Dietetics & Nutrition Technology Division, CSIR - Institute of Himalayan Bioresource Technology, Palampur, 176061, Himachal Pradesh, India; Academy of Scientific and Innovative Research, Ghaziabad, 201002, Uttar Pradesh, India.
Formulation Laboratory, Dietetics & Nutrition Technology Division, CSIR - Institute of Himalayan Bioresource Technology, Palampur, 176061, Himachal Pradesh, India; Academy of Scientific and Innovative Research, Ghaziabad, 201002, Uttar Pradesh, India.
Drug Discov Today. 2021 May;26(5):1319-1329. doi: 10.1016/j.drudis.2020.12.014. Epub 2020 Dec 24.
Human epidermal growth factor receptor 2 (HER2), a tyrosine kinase receptor with a molecular mass of 185kDa, is overexpressed in several cancers, such as breast, gastric, ovary, prostate, and lung. HER2 is a promising target in cancer therapy because of its crucial role in cell migration, proliferation, survival, angiogenesis, and metastasis through various intracellular signaling cascades. This receptor is an ideal target for the delivery of chemotherapeutic agents because of its accessibility to the extracellular domain. In this review, we highlight different HER2-targeting strategies and various approaches for HER2-targeted delivery systems to improve outcomes for cancer therapy.
人表皮生长因子受体 2（HER2）是一种分子量为 185kDa 的酪氨酸激酶受体，在多种癌症中过表达，如乳腺癌、胃癌、卵巢癌、前列腺癌和肺癌。由于其在细胞迁移、增殖、存活、血管生成和转移等多种细胞内信号通路中的关键作用，HER2 是癌症治疗的一个有前途的靶点。该受体是化疗药物传递的理想靶点，因为其可到达细胞外结构域。在这篇综述中，我们强调了不同的 HER2 靶向策略和各种 HER2 靶向递药系统的方法，以改善癌症治疗的效果。
